Key statistics
As of last trade Chemomab Therapeutics Ltd (2QV0:BER) traded at 1.73, -22.07% below its 52-week high of 2.22, set on Sep 04, 2024.
52-week range
Open | 1.74 |
---|---|
High | 1.74 |
Low | 1.73 |
Bid | 1.58 |
Offer | 1.72 |
Previous close | 1.71 |
Average volume | 2.00 |
---|---|
Shares outstanding | 18.51m |
Free float | 4.18m |
P/E (TTM) | -- |
Market cap | 34.24m USD |
EPS (TTM) | -7.69 USD |
Data delayed at least 15 minutes, as of Nov 13 2024 14:36 GMT.
More ▼
Announcements
- Chemomab Therapeutics to Report Third Quarter 2024 Financial Results and Provide a Business Update
- Chemomab Therapeutics Announces Late-Breaking Oral Presentation of CM-101 Phase 2 Results in Primary Sclerosing Cholangitis at AASLD The Liver Meeting® 2024
- Chemomab Therapeutics to Present at October 2024 Investor Conferences
- Chemomab Therapeutics to Present at September 2024 Investor Conferences
- Chemomab Therapeutics Announces Second Quarter 2024 Financial Results and Provides Corporate Update
- Chemomab Therapeutics to Report Second Quarter 2024 Financial Results and Provide a Business Update
- Chemomab Therapeutics Announces Closing of $10 Million Private Placement
- Chemomab Therapeutics Regains Compliance With Nasdaq Minimum Bid Price Requirement
- Chemomab Therapeutics Announces $10 Million Private Placement
- Chemomab Therapeutics Announces Positive Phase 2 Trial Results: CM-101 Achieves Primary and Secondary Endpoints Demonstrating Anti-Fibrotic, Anti-Inflammatory and Anti-Cholestatic Effects in Patients with Primary Sclerosing Cholangitis
More ▼